EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets

Samantha Bruno iD, Enrica Borsi iD, Agnese Patuelli, Lorenza Bandini, Manuela Mancini, Dorian Forte iD, Jacopo Nanni, Martina Barone, Alessandra Grassi, Gianluca Cristiano, Claudia Venturi, Valentina Robustelli iD und 10 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251810002 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Samantha Bruno und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Science (DIMEC), University of Bologna, 40138 Bologna, Italy. Hauptthemen laut MEDLINE: Aniline Compounds, Drug Resistance, Neoplasm, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, AIRC-Fellowship for Italy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is an aggressive hematologic neoplasia with a complex polyclonal architecture. Among driver lesions, those involving the FLT3 gene represent the most frequent mutations identified at diagnosis. The development of tyrosine kinase inhibitors (TKIs) has improved the clinical outcomes of FLT3-mutated patients (Pt). However, overcoming resistance to these drugs remains a challenge. To unravel the molecular mechanisms underlying therapy resistance and clonal selection, we conducted a longitudinal analysis using a single-cell DNA sequencing approach (MissionBioTapestri® platform, San Francisco, CA, USA) in two patients with FLT3-mutated AML. To this end, samples were collected at the time of diagnosis, during TKI therapy, and at relapse or complete remission. For Pt #1, disease resistance was associated with clonal expansion of minor clones, and 2nd line TKI therapy with gilteritinib provided a proliferative advantage to the clones carrying NRAS and KIT mutations, thereby responsible for relapse. In Pt #2, clonal architecture was less complex, and 1st line TKI therapy with midostaurin was able to eradicate the leukemic clones. Our results corroborate previous findings about clonal selection driven by TKIs, highlighting the importance of a deeper characterization of individual clonal architectures for choosing the best treatment plan for personalized approaches aimed at optimizing outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsDrug Resistance, Neoplasmfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationProtein Kinase InhibitorsStaurosporineHumansGTP PhosphohydrolasesMembrane ProteinsProto-Oncogene Proteins c-kitPyrazinesSequence Analysis, DNASingle-Cell Analysis

Stichwörter der Autor:innen

FLT3 mutationsacute myeloid leukemiaclonal architectureclonal evolutiontyrosine kinase inhibitors

Substanzen

Aniline CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibGTP PhosphohydrolasesKIT protein, humanMembrane ProteinsmidostaurinNRAS protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical and Surgical Science (DIMEC), University of Bologna, 40138 Bologna, Italy.
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero, Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", 940138 Bologna, Italy.

ORCID-Profile: Samantha Bruno, Enrica Borsi, Dorian Forte, Valentina Robustelli, Andrea Poletti, Michele Cavo, Emanuela Ottaviani

Förderung

  • Italian Ministry of Health
  • AIRC-Fellowship for Italy

Zitieren

APA

Bruno, S., Borsi, E., Patuelli, A., Bandini, L., Mancini, M., Forte, D., Nanni, J., Barone, M., Grassi, A., Cristiano, G., Venturi, C., Robustelli, V., Atzeni, G., Mosca, C., De Santis, S., Monaldi, C., Poletti, A., Terragna, C., Curti, A., …, & Ottaviani, E. (2024). Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251810002

Vancouver

Bruno S, Borsi E, Patuelli A, Bandini L, Mancini M, Forte D, et al. Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251810002

BibTeX
@article{Bruno2024,
  author = {Bruno, Samantha and Borsi, Enrica and Patuelli, Agnese and Bandini, Lorenza and Mancini, Manuela and Forte, Dorian and Nanni, Jacopo and Barone, Martina and Grassi, Alessandra and Cristiano, Gianluca and Venturi, Claudia and Robustelli, Valentina and Atzeni, Giulia and Mosca, Cristina and De Santis, Sara and Monaldi, Cecilia and Poletti, Andrea and Terragna, Carolina and Curti, Antonio and Cavo, Michele and Soverini, Simona and Ottaviani, Emanuela},
  title = {Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251810002}
}
Kostenlos starten →